Geneva Capital Management LLC lessened its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 4.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 38,546 shares of the company’s stock after selling 1,696 shares during the period. Geneva Capital Management LLC’s holdings in IDEXX Laboratories were worth $20,128,000 as of its most recent SEC filing.
A number of other institutional investors have also recently made changes to their positions in IDXX. Aurora Investment Managers LLC. purchased a new position in IDEXX Laboratories in the 2nd quarter worth approximately $2,442,000. National Pension Service boosted its stake in IDEXX Laboratories by 5.6% during the 2nd quarter. National Pension Service now owns 129,305 shares of the company’s stock valued at $68,071,000 after purchasing an additional 6,885 shares during the last quarter. Howard Capital Management LLC purchased a new stake in IDEXX Laboratories during the 3rd quarter valued at $1,249,000. NewEdge Advisors LLC boosted its stake in IDEXX Laboratories by 60.9% during the 1st quarter. NewEdge Advisors LLC now owns 15,221 shares of the company’s stock valued at $8,552,000 after purchasing an additional 5,761 shares during the last quarter. Finally, Arizona State Retirement System increased its holdings in shares of IDEXX Laboratories by 4.9% in the 2nd quarter. Arizona State Retirement System now owns 22,772 shares of the company’s stock worth $11,988,000 after purchasing an additional 1,074 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.
Wall Street Analysts Forecast Growth
IDXX has been the topic of a number of research analyst reports. Morgan Stanley upped their price target on IDEXX Laboratories from $805.00 to $810.00 and gave the company an “overweight” rating in a report on Tuesday, November 3rd. Citigroup lifted their price objective on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a report on Wednesday, August 5th. The Goldman Sachs Group assumed coverage on IDEXX Laboratories in a report on Friday, October 16th. They issued a “buy” rating and a $740.00 price objective for the company. JPMorgan Chase & Co. decreased their target price on IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating for the company in a research report on Friday, October 16th. Finally, KeyCorp initiated coverage on shares of IDEXX Laboratories in a research note on Monday, October 12th. They set a “sector weight” rating on the stock. Seven research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $717.27.
View Our Latest Stock Analysis on IDEXX Laboratories
Insider Activity at IDEXX Laboratories
In other IDEXX Laboratories news, Director Lawrence D. Kingsley sold 2,203 shares of the stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $532.08, for a total value of $1,172,172.24. Following the transaction, the director owned 9,568 shares of the company’s stock, valued at approximately $5,090,941.44. This represents a 18.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Sharon Underberg sold 8,906 shares of the firm’s stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $688.59, for a total value of $6,132,582.54. Following the completion of the transaction, the executive vice president directly owned 7,169 shares in the company, valued at $4,936,501.71. The trade was a 55.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 41,428 shares of company stock valued at $28,567,934 in the last 90 days. 0.79% of the stock is owned by company insiders.
IDEXX Laboratories Price Performance
Shares of IDXX opened at $704.23 on Monday. The firm has a market cap of $55.49 billion, a PE ratio of 47.49 and a beta of 1.55. The company has a current ratio of 1.19, a quick ratio of 0.88 and a debt-to-equity ratio of 0.16. The firm has a fifty day simple moving average of $562.41 and a two-hundred day simple moving average of $573.52. IDEXX Laboratories, Inc. has a 1-year low of $500.61 and a 1-year high of $769.98.
IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last released its quarterly earnings results on Monday, November 2nd. The company reported $3.96 earnings per share for the quarter, beating the consensus estimate of $3.71 by $0.25. The firm had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.19 billion. IDEXX Laboratories had a return on equity of 71.04% and a net margin of 25.36%. The company’s revenue was up 9.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.22 EPS. On average, equities analysts anticipate that IDEXX Laboratories, Inc. will post 15.05 EPS for the current year.
About IDEXX Laboratories
IDEXX Laboratories develops and sells diagnostic, technology and software products for veterinary, livestock and water-testing markets. Its veterinary offerings include in-clinic diagnostic instruments and tests, reference laboratory services, digital imaging and practice-management software that help veterinary professionals assess animal health and manage their practices. The company also provides diagnostic tests and related services for livestock and poultry, as well as products used to monitor water quality.
Further Reading
- Five stocks we like better than IDEXX Laboratories
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
